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Roche, Basel, SwitzerlandA B S T R A C TObjectives: To estimate the cost-effectiveness of tocilizumab (TCZ)
monotherapy (Mono) versus adalimumab (ADA) Mono from the US
payer perspective in patients with rheumatoid arthritis for whom
methotrexate is inappropriate. Methods: We compared TCZ Mono (8
mg/kg monthly) with ADA Mono (40 mg every other week), using
efﬁcacy results from a head-to-head study, ADalimumab ACTemrA
(ADACTA). We calculated the incremental cost per responder (achieve-
ment of American College of Rheumatology [ACR] 20% improvement
criteria, ACR 50% improvement criteria, ACR 70% improvement criteria,
or low disease activity score) for TCZ versus ADA at 6 months. A
patient-level simulation was used to estimate the lifetime incremental
cost per quality-adjusted life-year (QALY) of initiating treatment with
TCZ Mono versus ADAMono. Both drugs are followed by an etanercept-
certolizumab-palliative care sequence. Nonresponders discontinue at 6
months; responders experience a constant probability of discontinua-
tion. Discontinuers move to the next treatment. ACR responses
produce changes in the Health Assessment Questionnaire (HAQ) score.
We mapped the HAQ score to utility to estimate QALYs. Costs includeee front matter & 2015 Published by Elsevier Inc.
(ISPOR). This is an open access article under the
ons.org/licenses/by-nc-nd/3.0/).
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ondence to: Josh J. Carlson, School of Pharmacy,
98195, USA.those related to hospitalization and those related to treatment (drug
acquisition, administration, and monitoring). Probabilistic and one-way
sensitivity analyses were conducted, along with several scenario
analyses. Results: Compared with ADA, TCZ was more effective, with
an estimated 6-month incremental cost ranging from $6,570 per addi-
tional low disease activity score achiever to $14,265 per additional ACR
70% improvement criteria responder. The lifetime incremental cost-
effectiveness ratio was $36,944/QALY. Conclusions: TCZ Mono is pro-
jected to be cost-effective compared with ADA Mono in patients with
severe rheumatoid arthritis for whom methotrexate is not appropriate,
from a US payer perspective.
Keywords: anti-TNF-α, cost-effectiveness, rheumatoid arthritis,
tocilizumab.
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Pharmacoeconomics and Outcomes Research (ISPOR). This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease
leading to inﬂammation in joints and connective tissue, along
with other systemic effects. It is associated with substantial
economic and health-related quality-of-life impacts [1–3].
According to the American College of Rheumatology (ACR)
guidelines, treatment for early RA should begin with the use of
traditional (nonbiologic) disease-modifying antirheumatic drugs
(DMARDs), most commonly methotrexate (MTX) [4]. For patients
who do not tolerate MTX, alternate conventional DMARDs are
often tried. For patients with established RA (Z6-month duration)
and more severe disease, a biologic DMARD is often added [4].Although many patients treated with a biologic agent continue to
use traditional DMARDs in combination, studies have indicated
that patients often discontinue these agents or have poor
adherence because of intolerance, lack of efﬁcacy, or other factors
[5]. As a result, roughly 30% of the patients using a biologic
DMARD receive it as monotherapy (Mono) [6,7]. In patients who
are eligible to receive a biologic DMARD, antagonists to tumor
necrosis factor alpha (anti–TNF-α) are generally started ﬁrst.
There is evidence to suggest, however, that other available
biologic DMARDs, with different mechanisms of action, are
similarly effective when used in combination with MTX after
the failure of traditional DMARDs for the treatment of RA, with
mean response rates around 60% to 70% [8]. Still, when used ason behalf of International Society for Pharmacoeconomics and
CC BY-NC-ND license
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Fig. 1 – Use of HAQ Score in the lifetime model. The model
captures changes in disease severity based on results from
the HAQ, which then impacts utility, mortality rate and
hospitalization rates in the model. HAQ, Health Assessment
Questionnaire; QALY, quality-adjusted life year.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 7 3 – 1 7 9174Mono, there may be differences in efﬁcacy among biologic treat-
ment options [9–11].
Tocilizumab (TCZ) is a humanized monoclonal antibody that
inhibits the interleukin-6 receptor. Its safety and efﬁcacy were
demonstrated in three large phase III trials, for use in combina-
tion with MTX in patients with RA with inadequate response to
traditional DMARDs [12–14]. More recently, a phase IV study,
ADalimumab ACTemrA (ADACTA), compared monthly TCZ Mono
head-to-head with a commonly used anti–TNF-α (adalimumab
[ADA] Mono administered every other week [EOW]) in biologically
naive patients with severe active RA who were intolerant to MTX
or in whom continued MTX treatment was considered inappro-
priate. ADACTA was a 24-week, multicenter, randomized, double-
blind, parallel-group study. Results indicated that TCZ Mono was
superior to ADA Mono in reducing the signs and symptoms of RA
within this patient population [10]. The cost-effectiveness of TCZ
Mono relative to ADA Mono, however, has not been assessed. The
objective of this study was to estimate the cost-effectiveness of
monthly TCZ Mono versus ADA Mono EOW for biologically naive
patients with severe active RA who are considering the use of a
biologic and are not candidates for continued MTX, from the US
payer perspective.Fig. 2 – Lifetime model schematic. The schematic
demonstrates how treatment inﬂuences HAQ score within
the model. ACR, American College of Rheumatology; ADA,
adalimumab; HAQ, Health Assessment Questionnaire; RA,
rheumatoid arthritis; TCZ, tocilizumab.Methods
We determined the cost-effectiveness of treatment initiation
with TCZ (8 mg/kg intravenously every 4 weeks) Mono compared
with treatment initiation with ADA (40 mg subcutaneously EOW)
Mono over two time horizons, 6 months and lifetime. The 6-
month analysis was used to determine the incremental cost per
additional clinical response with TCZ Mono versus ADA Mono
over the treatment initiation phase, which aligns with the
duration of the randomized, double-blind phase in ADACTA.
Achievement of four RA clinical response levels was assessed:
ACR 20% improvement criteria (ACR20), ACR 50% improvement
criteria (ACR50), ACR 70% improvement criteria (ACR70) and low
disease activity score (LDAS). The ACR response levels have been
deﬁned by the ACR and are widely used in RA clinical trials
[15,16]. The ACR deﬁnes LDAS as having a 28-joint disease
activity score of at least 2.6 but less than 3.2 [4]. Efﬁcacy for
TCZ and ADA was obtained directly from ADACTA [10].
A patient-level simulation model (10,000 patients) was used to
estimate the incremental cost per quality-adjusted life-year(QALY) of initiating treatment with TCZ Mono or ADA Mono over
a lifetime time horizon. Patient characteristics at entry into the
model were based on baseline characteristics from ADACTA [10].
Patients enter the model after discontinuing MTX and begin
treatment with either TCZ Mono or ADA Mono. In clinical practice,
patients with RA generally progress through multiple treatments
over time. Therefore, both TCZ and ADA are followed by an
etanercept-certolizumab-palliative care treatment sequence in
the model. Patients are reassessed every 6 months, at which point
they can remain on current treatment, transition to the next
treatment, or move to the absorbing state, death.
Treatment response is assessed at 6 months, and patients are
categorized into one of four commonly used RA clinical response
levels: ACR70, ACR50, ACR20, or nonresponder. These were
chosen because they are commonly used and reported measures
of treatment efﬁcacy in clinical and cost-effectiveness studies in
RA [17]. Responders continue on current treatment but experi-
ence a constant 16% probability of discontinuation because of
intolerance or lack of efﬁcacy thereafter. This rate is the average
discontinuation rate observed in ADACTA (15% TCZ, 17% ADA)
and is assumed to be the same for all treatments [10]. After
discontinuation, either due to nonresponse at 6 months or later
withdrawal, patients move on to the next treatment in the
sequence. Response rates are treatment-speciﬁc and are derived
from ADACTA for TCZ and ADA [10]. Because no head-to-head
data were available for etanercept and certolizumab, response
rates are estimated on the basis of results of a mixed treatment
comparison (MTC) [18,19]. The available evidence for these
agents, however, is from inadequate responders to traditional
DMARDs, while in the model they are used after inadequate
response to biologic DMARDs. Studies have shown that response
rates are lower for patients with RA switching to a different anti–
TNF-α, after a previous anti–TNF-α failure, than for those receiv-
ing their ﬁrst anti–TNF-α [20]. Therefore, response rates for these
agents were reduced in the model (assumed to be 84% of those
from the MTC) [20]. The response rates for the palliative care
group were assumed to equal the response rate for the placebo
group from the MTC. Clinical trials generally report ACR response
rates as cumulative categories, wherein ACR20/50/70 includes
individuals achieving at least ACR20 and ACR50/70 includes
individuals achieving at least ACR50. To derive mutually exclu-
sive proportions for assigning patients to response categories, the
rates were transformed as follows: 1) the ACR50/70 proportions
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 7 3 – 1 7 9 175were removed from the ACR20/50/70 group to create the ACR20
group, and 2) the ACR70 proportion was removed from the
ACR50/70 group to create separate ACR50 and ACR70 groups.
Those without an ACR20/50/70 response were nonresponders.
The model captures changes in disease severity on the basis
of results from the Health Assessment Questionnaire (HAQ), a
patient-reported outcome instrument that is commonly used in
musculoskeletal disorders to measure functional status [21]. The
HAQ Disability Index score then impacts patient utility, mortal-Table 1 – Key model parameters.
Input Base
Population characteristics
Age (y), mean 54
Body weight (kg) 77
Sex: female, % 80
Starting HAQ score, mean 1.65
Response, % of patients achieving ACR20, ACR50, ACR70
Tocilizumab 18, 15, 33
Adalimumab EOW 22, 10, 18
Adalimumab weekly 13, 17, 27
Etanercept* 20, 24, 10
Certolizumab* 21, 17, 8
Palliative care 11, 5, 1
LDAS
Tocilizumab 52
Adalimumab EOW 20
Adalimumab weekly 31
HAQ score change by state, mean
Nonresponder, 6 mo 0.11
ACR20, 6 mo 0.44
ACR50, 6 mo 0.76
ACR70, 6 mo 1.07
Palliative care (6 mo) 0.03
Hospital days per year by HAQ score, mean
0.0–0.5 0.26
0.6–1.0 0.13
1.1–1.5 0.51
1.6–2.0 0.72
2.1–2.5 1.86
2.6–3.1 4.16
Unit costs ($)
Hospitalization (DRG 547) 1251
Treatment-related costs
Tocilizumab (80-mg vial) 287
Etanercept (50-mg syringe) 603
Adalimumab (40-mg syringe) 1170
Certolizumab (400-mg syringe) 2220
Infusion, 1-h (CPT 96413) 105
Outpatient visit (CPT 99202) 55
Outpatient visit (CPT 99212) 32
Chest x-ray (CPT 71034) 64
Other inputs
Discontinuation rate (%), 6 mo 16
Ratio TNF-IR to DMARD-IR 0.84
Ratio ADA weekly to ADA EOW
ACR20, ACR50, ACR70 1.16, 1.58, 1.48
Achievement of LDAS 1.55
HAQ mortality risk multiplier 1.33
ACR20, American College of Rheumatology 20% improvement criteria; AC
criteria; ADA, adalimumab; CPT, Current Procedural Terminology; DMA
group; EOW, every other week; HAQ, Health Assessment Questionnaire; I
necrosis factor.
* Before adjustment for TNF-IR.ity rate, and hospitalization rate in the model (Fig. 1). The
patient-level simulation approach allows the HAQ score to
change over time as a function of baseline HAQ, treatment
status, and time in the palliative care phase. The model
schematic demonstrates how treatment inﬂuences the HAQ
score within the model (Fig. 2). Each response level is linked to
a change in the HAQ score, wherein a higher response leads to a
greater reduction in the HAQ score (greater improvement). The
relationship between response and the HAQ score was obtainedLow High Source
48 59 [12]
70 85 –
72 89 [12]
1.49 1.82 [10]
17, 13, 29 20, 16, 36 [10]
19, 9, 16 23, 11, 20 [10]
12, 16, 24 15, 19, 29 [10,33]
18, 22, 9 23, 26, 11 [18,19]
19, 15, 7 23, 19, 8 [18,19]
9, 5, 1 12, 6, 1 [18,19]
46 57 [10]
18 22 [10]
28 34 [10,33]
0.24 0.02 [10]
0.55 0.33 [10]
0.94 0.58 [10]
1.22 0.92 [10]
0.02 0.04 [22]
0 26 [29,30]
0 21 [29,30]
0 83 [29,30]
0 25 [29,30]
0 48 [29,30]
0 50 [29,30]
875 1626 [28]
244 330 [27]
513 693 [27]
994 1345 [27]
1887 2553 [27]
73 136 [28]
38 71 [28]
23 42 [28]
45 84 [28]
5 30 [10]
0.75 0.92 [20]
1.04, 1.43, 1.34 1.28, 1.74, 1.63 [33]
1.39 1.70 [33]
1.10 1.61 [25,26]
R50, ACR 50% improvement criteria; ACR70, ACR 70% improvement
RD, disease-modifying antirheumatic drug; DRG, diagnosis related
R, inadequate response; LDAS, low disease activity score; TNF, tumor
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 7 3 – 1 7 9176from ADACTA but is assumed to be the same for all treatments
[10]. As a result, the impact of treatment on the HAQ score over
the ﬁrst 6 months is based entirely on the ACR 20/50/70 response
level. After the ﬁrst 6 months, the HAQ score is assumed to
remain constant while on biologic treatment [22]. Patients who
discontinue treatment experience a rebound in the HAQ score,
returning to their starting HAQ score (i.e., the HAQ score before
treatment initiation), until they begin their next treatment [23].
Patients who move through all treatment options and enter
“palliative care” experience a constant increase in disease
severity, modeled as an increase of 0.03 in the HAQ score every
6 months [22]. Table 1 presents the parameter inputs used in the
economic model.
To generate preference-based quality-of-life estimates,
the HAQ score was mapped to the EuroQol ﬁve-dimensional
questionnaire (EQ-5D), using pooled data from TCZ clinical trials
[12–14]. The utility mapping algorithm used in the model (Equa-
tion 1) has been published previously and assumes that improve-
ments carry greater value at higher disease severities [24].
EQ5D ¼ 0:82 – ð0:11HAQÞ – ð0:07HAQ2Þ ð1Þ
Mortality rates were based on life table estimates, adjusted for
RA-associated disability. The mortality risk adjustment (Equation
2) is dependent on the HAQ score and has been used in previous
RA models [25,26].
RAspecific mortality rate¼ Mortality rate from life table  1:33HAQ 
ð2Þ
Unit cost estimates are derived from published sources and are
presented in Table 1 [27,28]. Costs are in 2013 US dollars. Modeled
costs fell into two categories: treatment-related costs and hospi-
talization costs. Treatment-related costs included those for drug
acquisition, administration, and monitoring. Drug acquisition
cost was unique to each agent and was based on the wholesale
acquisition cost [27]. The administration cost for TCZ included a
1-hour intravenous infusion (Current Procedural Terminology
[CPT] 96413) for each dose (every 4 weeks) [28]. All other agents
in the model are administered subcutaneously, and so the
administration cost was based on an annual outpatient visit to
obtain a new prescription (CPT 99202). Monitoring costs were
considered to be the same across agents and included costs for
physician visits (CPT 99202, 99212) and chest X-rays (CPT 71034),
to check for signs of tuberculosis before treatment initiation. The
number of inpatient hospital days (diagnosis-related group 547)
was estimated on the basis of the HAQ score using the methods
developed by Kobelt et al. and data from the Norfolk Arthritis
Register, a large UK-based RA registry established in 1989
(Table 1) [29–32]. Overall, annual treatment-related costs were
as follows: TCZ $30,547, ADA EOW $30,800, ADA weekly $61,234,
etanercept $31,717, and certolizumab $29,226. Costs and QALYs
were discounted at 3%.
Sensitivity Analyses
Sensitivity analyses were used to test the robustness of results
for the lifetime model. First, overall parameter uncertainty was
tested using one-way (inputs and ranges are provided in Table 1)
and probabilistic sensitivity analyses (included 2,000 simulations
of 10,000 patients; inputs and parameter distributions are pro-
vided in Appendix A in Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2014.10.013). Then, several scenario anal-
yses were conducted. The ﬁrst compared treatment initiation
with TCZ (8 mg/kg intravenously every 4 weeks) Mono to treat-
ment initiation with ADA (40 mg subcutaneously weekly) Mono.
Because weekly ADA dosing was not included as one of the
randomized treatment groups in ADACTA, response rates for
ADA weekly were estimated by increasing the ADA responseobserved in ADACTA, using a ratio derived from a study inves-
tigating the efﬁcacy of both ADA dosage regimens (response to
ADA weekly:response to ADA EOW) [33]. In addition, three
scenarios were carried out within the lifetime model to further
investigate the impact of speciﬁc parameters: 1) the cost of ADA
was varied across a reasonable range (15%), 2) the ratio of
response of ADA weekly to ADA EOW was increased by 10%, and
3) TCZ Mono was compared with ADA Mono across a range of
ADA dosing distributions (from 0% weekly/100% EOW to 100%
weekly/0% EOW).Results
The results of the model are presented in Table 2. When
comparing TCZ Mono with ADA Mono EOW, TCZ was projected
to be more effective but also more costly. Over 6 months, the
proportion of patients achieving each response level (ACR 20/50/
70 and LDAS) was higher for TCZ Mono than for ADA Mono, with
incremental response proportions ranging from 15% for ACR70 to
32% for LDAS. Over the 6-month period, TCZ cost $2,083 more
than did ADA ($15,636 vs. $13,553). As a result, the incremental
cost-effectiveness ratio (ICER) for TCZ Mono over 6 months
ranged from $6,570 per additional achievement of LDAS to
$14,265 per additional achievement of ACR70 response. In the
lifetime analysis, TCZ resulted in the incremental gain of 0.04
life-years (TCZ 15.93 vs. ADA 15.88) and 0.23 QALYs (TCZ 6.66 vs.
ADA 6.43), while increasing cost by $8,532, compared with ADA
(TCZ $178,643 vs. ADA $170,111). This produced an ICER of
$36,944/QALY for TCZ Mono compared with ADA Mono.Sensitivity Analyses
Results of the lifetime analysis were most sensitive to changes in
drug acquisition cost, body weight, ACR response rates, and the
discontinuation rate (Fig. 3). Scenario analyses further investi-
gated the impact of ADA dosing frequency and uncertainty in
ADA cost and other parameters of interest (Table 2). TCZ Mono
was dominant compared with ADA Mono EOW when the cost of
ADA was increased by 15%, while the ICER was $74,592/QALY
when ADA cost was decreased by 15%. In the scenario comparing
TCZ Mono with ADA Mono weekly, TCZ was more effective and
less costly than ADA, in both the 6-month and lifetime analyses.
TCZ Mono remained dominant compared with ADA Mono weekly
when varying ADA costs and response rates in additional scenar-
ios. When TCZ Mono was compared with ADA Mono, using a
range of ADA Mono dosing distributions (weekly vs. EOW), TCZ
remained dominant when at least 12% of ADA-treated patients
were dosed weekly. Using the dosing distribution derived from a
US health care claims analysis (94% EOW, 6% every week)
resulted in an ICER of $18,895/QALY [34]. The results of the
probabilistic sensitivity analyses demonstrate that there is a
more than 50% probability that TCZ Mono is cost-effective
compared with ADA Mono EOW if the willingness to pay is at
least $40,000/QALY (Fig. 4). The probability that TCZ Mono is cost-
effective compared with ADA Mono weekly is 100% at all levels of
willingness to pay.Discussion
ADACTA investigators found that TCZ Mono was superior to
ADA Mono dosed EOW in reducing the signs and symptoms of
RA in biologically naive patients with severe active RA in
whom MTX treatment is considered inappropriate [10]. The
present study expands on this ﬁnding by estimating the
lifetime cost-effectiveness of TCZ Mono compared with
Table 2 – Model results.
TCZ Mono ADA Mono Difference* Incremental cost-effectiveness ratio
TCZ Mono vs. ADA Mono every other week (lifetime model)
Costs ($) 178,643 170,111 8,532
Life-years 15.93 15.88 0.04
QALYs 6.66 6.43 0.23 $36,944/QALY
TCZ Mono vs. ADA Mono every other week (6-mo model)
Costs ($) 15,863 13,780 2,083
ACR20 (%) 65 49 16 $13,351/ACR20 response
ACR50 (%) 47 28 19 $10,735/ACR50 response
ACR70 (%) 33 18 15 $14,265/ACR70 response
LDAS (%) 52 20 32 $6,570/LDAS
TCZ Mono vs. ADA Mono weekly (lifetime model)
Costs ($) 178,643 242,167 63,525
Life-years 15.93 15.91 0.02
QALYs 6.66 6.57 0.09 TCZ dominates
TCZ Mono vs. ADA Mono weekly (6-mo model)
Costs ($) 15,863 26,676 10,813
ACR20 (%) 65 57 8
ACR50 (%) 47 44 3 TCZ dominates
ACR70 (%) 33 27 6
LDAS (%) 52 31 21
TCZ Mono vs. ADA Mono weekly (lifetime model scenarios)
15% increase in cost of ADA
Costs ($) 178,643 261,873 83,230
QALYs 6.66 6.57 0.09 TCZ dominates
15% decrease in cost of ADA
Costs ($) 178,643 222,462 44,820
QALYs 6.66 6.57 0.09 TCZ dominates
10% increase in ratio of response rates for ADA weekly to ADA every other week
Costs ($) 178,643 252,720 74,077
QALYs 6.66 6.64 0.02 TCZ dominates
TCZ Mono vs. ADA Mono every other week (lifetime model scenarios)
15% increase in cost of ADA
Costs ($) 178,643 178,805 162
QALYs 6.66 6.43 0.23 TCZ dominates
15% decrease in cost of ADA
Costs ($) 178,643 161,416 17,226
QALYs 6.66 6.43 0.23 $74,592/QALY
TCZ Mono vs. current dosing distribution for ADA Mono in the United States*
Costs ($) 178,643 174,435 4,208
QALYs 6.66 6.44 0.22 $18,895/QALY
ACR20, American College of Rheumatology 20% improvement criteria; ACR50, ACR 50% improvement criteria; ACR70, ACR 70% improvement
criteria; ADA, adalimumab; LDAS, low disease activity score; Mono, monotherapy; QALY, quality-adjusted life-year; TCZ, tocilizumab.
* 94% ADA Mono 40 mg every other week, 6% ADA Mono 40 mg every week.
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the short-term ICERs (e.g., $13,351/ACR20 response) are con-
sistent with cost-effectiveness ratios reported for other bio-
logic agents in similar populations [17,35]. In addition, in a
scenario analysis comparing TCZ Mono with weekly ADA
Mono, TCZ Mono is projected to be both more effective and
less costly.
These results are noteworthy, given that anti-TNF-αs are
generally used as ﬁrst-line treatment in patients with RA eligible
for biologic DMARDs. This study coupled with the results of the
ADACTA trial and related clinical trials performed to date add to
the growing literature demonstrating the positive clinical and
economic impacts of the novel interleukin-6 receptor inhibitor,
TCZ, in patients with severe RA.
In addition to our ﬁndings, the cost-effectiveness of TCZ in
combination with MTX over a lifetime horizon has been previ-
ously demonstrated, from the Italian payer’s perspective, when
introduced before or substituted for anti–TNF-α’s in patients withinadequate response to traditional DMARDs [24]. Although the
main treatment comparator and sequencing were different than
in the present study, TCZ was either dominant or considered
cost-effective in all scenarios, and the probabilistic sensitivity
analyses demonstrated roughly a 100% probability of TCZ being
cost-effective at a willingness-to-pay value of €50,000/QALY.
Although conducted in a different patient population and in a
different country, the results of this study are in line with our
ﬁndings.
The results of the lifetime model were most sensitive to
changes in drug acquisition cost. Given that these costs vary
among US payers, results may differ for individual payers. The
wholesale acquisition cost, however, is a reasonable, and com-
monly used, unit cost estimate.
This study had several limitations, the greatest of which was
the lack of head-to-head data for the entire treatment sequence.
ADACTA is the only head-to-head trial to date that has tested the
superiority of Mono with one biologic DMARD over another. ADA
Fig. 3 – One-way sensitivity analysis (tocilizumab
monotherapy vs. adalimumab monotherapy every other
week). ACR, American College of Rheumatology; HAQ,
Health Assessment Questionnaire; QALY, Quality Adjusted
Life Years; TNF, tumor necrosis factor.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 7 3 – 1 7 9178is a widely used ﬁrst-line biologic DMARD, and is thus considered
a good comparator. The lack of head-to-head data, however, also
means that efﬁcacy data for agents used later in the treatment
sequence are based on the results of an MTC. As more head-to-
head data become available, these results should be updated. The
MTC also provided adjusted rates for TCZ and ADA. We chose to
use the rates directly from ADACTA for our base case because
these were considered the best data to inform the direct compar-
ison. Using the rates from the MTC for TCZ and ADA provided
similar results (ICER $38,375). Head-to-head data were also
unavailable for comparing all dosage regimens of ADA and TCZ.
Although ADA may be dosed weekly or EOW, only EOW dosing
was used within ADACTA. Van de Putte et al. [33] demonstrated
that weekly dosing of ADA Mono improves its efﬁcacy [33]. In
addition, the ADA package insert states that weekly dosing may
be recommended in patients with RA receiving ADA Mono [36].
Therefore, we felt that it was important to include this dosing
option as a scenario in the model. We were able to estimate ADA
weekly efﬁcacy by adjusting the results from ADACTA using dataFig. 4 – Cost-effectiveness acceptability curve (tocilizumab
monotherapy vs. adalimumab monotherapy every other
week). The probabilistic sensitivity analyses included 2,000
simulations of 10,000 patients. ICER, incremental cost-
effectiveness ratio; QALY, quality-adjusted life years.from van de Putte et al., who investigated the efﬁcacy of both
ADA doses [10,33]. In addition, we conducted an additional
scenario analysis in which the ratio of response of ADA weekly
to ADA EOW was increased by 10%, thus improving the effective-
ness of ADA weekly. Results of all analyses demonstrated that
TCZ Mono was dominant over ADA Mono weekly. In an addi-
tional scenario analysis using a range of ADA Mono dosing
distributions, TCZ remained dominant when at least 12% of
ADA-treated patients were dosed weekly. The availability of data
was also limited for TCZ. The US label for TCZ recommends
starting patients on 4 mg/kg and escalating the dose to 8 mg/kg
on the basis of clinical response. Because the 4-mg/kg dose was
not used in ADACTA and has not yet been evaluated in the Mono
population, it could not be included in the model.
Our model was also limited by its reliance on ACR rates and
the associated mean change in the HAQ score from baseline. In
this trial-based analysis, however, the two patient groups were
relatively homogenous at baseline and we lacked data to
inform an evaluation of the potential impact of patient hetero-
geneity at baseline. In addition, the HAQ may not fully capture
disease severity. However, it is a psychometrically validated
outcome measure that has been widely used in RA for many
years [21]. Furthermore, using the HAQ to inform costs and
outcomes is a common method in economic models of RA [37].
Finally, though the model predicts a greater decrease in the
HAQ score on initiation with TCZ (vs. ADA), due to its superior
ACR response rates, the ADACTA trial did not ﬁnd a statistically
signiﬁcant difference in the HAQ scores between the two
agents (0.2; 95% conﬁdence interval 0.3 to 0.0; P ¼ 0.0653)
[10]. This may be attributable to the fact that change in the HAQ
score was a secondary outcome, and ADACTA was not powered
to show a statistically signiﬁcant difference in the HAQ score.
Finally, the model did not explicitly account for adverse
effects. Because the safety proﬁles of biologic DMARDs are
similar, it is not expected that their inclusion would signiﬁcantly
alter the results. In addition, costs of adverse effects are captured
indirectly through treatment discontinuation, which leads to
increases in the HAQ score and, therefore, increases in costs.
Quality-of-life decrements are also incorporated indirectly,
through changes in the HAQ score (mapped to the EQ-5D), on
the basis of data derived from TCZ clinical trials.Conclusions
From a US payer perspective, TCZ (8 mg/kg every 4 weeks) Mono
is more effective and projected to be cost-effective compared
with ADA Mono 40 mg EOW and dominant when compared with
ADA Mono 40 mg weekly in patients with severe RA for whom
MTX is not appropriate.Acknowledgment
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